Articles

Although 5 years of neoadjuvant endocrine therapy improves disease-free survival in patients with early-stage breast cancer, the optimal duration of adjuvant therapy beyond 5 years has yet to be established. Results of a new study, suggesting that longer is not necessarily better, provide further insight on this topic. Read More ›

An evaluation of more than 200 patients with breast cancer showed a near doubling of the risk for contralateral disease with dense breast tissue. This information may help clinicians counsel patients on their personal risk and options for treatment and surveillance. Read More ›

Adding pertuzumab to standard therapy in women with HER2+ /HR+ locally advanced or metastatic breast cancer increased PFS, with no new safety signals identified. Read More ›

No significant difference was found in survival between BRCA gene carriers and noncarriers among young patients with breast cancer. In addition, a consistent survival advantage was found in favor of BRCA carriers presenting with triple-negative breast cancer. Read More ›

New data confirm the heterogeneity of HER2-positive breast cancer and may identify a subgroup of patients who benefit from dual HER2 blockade without the use of chemotherapy. Read More ›

Surviving cancer is the start of a new journey for many individuals. Cancer survivors face a multitude of challenges, including prevention of new and recurrent cancers; interventions for illnesses secondary to cancer and its treatment; concerns related to employment, insurance, and disability; and coordination between specialists and primary care providers. Read More ›